Clinical Trial Update: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating everolimus alone or in combination with pasireotide LAR for advanced pancreatic neuroendocrine tumors was terminated, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Everolimus (everolimus)
• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Islet Cell Tumor | Phase 2 | Status: TERMINATED | Results posted: 2016-12-20